Personalized Therapy in Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Excision repair cross complementing 1 (ERCC1) ribonucleotide reductase M1 (RRM1) and
thymidylate synthase(TS) are molecular determinants that predict sensitivity or resistance to
platinum agents 、 gemcitabine and pemetrexed respectively.
Tailored therapy using these molecular determinants suggested patient benefit in a previously
reported phase 2 trial. Here, we designed a study for an individual patient analysis of
prospectively accrued patients who were treated with the "personalized therapy" approach
versus other standard approaches.
Phase:
Phase 2
Details
Lead Sponsor:
Guangzhou Medical University
Collaborator:
The First Affiliated Hospital of Guangzhou Medical University